Psicosis inducida por cannabis: características clínicas y su diferenciación con la esquizofrenia con y sin consumo de cannabis asociado

Referències bibliogràfiques

• Allegri, F., Belvederi, M., Paparelli, A., Marcacci, T., Braca, M., Menchetti, M., … Tarricone, I. (2013). Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Research, 210, 368-370. doi:10.1016/j.psychres.2013.06.010
• APA, American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th Edition). Washington, DC: American Psychiatric Association.
• Andréasson, S., Allebeck, P., Engström, A. y Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 26, 1483-1486.
• Arendt, M., Rosenberg, R., Foldager, L., Perto, G. y Munk-Jørgensen, P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry, 187, 510-515.
• Baeza, I., Graell, M., Moreno, D., Castro-Fornieles, J., Parellada, M., González-Pinto, A., … Arango, C. (2009). Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research, 113, 129-137. doi:10.1016/j.schres.2009.04.005
• Baldacchino, A., Hughes, Z., Kehoe, M., Blair, H., Teh, Y., Windeatt, S. y Crome, I. B. (2012). Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. American Journal on Addictions, 21, 88-98. doi:10.1111/j.1521-0391.2012.00295.x
• Barratt, M. J., Cakic, V. y Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32, 141-146. doi:10.1111/j.1465-3362.2012.00519.x
• Bersani, G., Orlandi, V., Kotzalidis, G. D. y Pancheri, P. (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience, 252, 86-92.
• Boydell, J., Dean, K., Dutta, R., Giouroukou, E., Fearon, P. y Murray, R. (2007). A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophrenia Research, 93, 203-210.
• Butler, S. F., Redondo, J. P., Fernandez, K. C. y Villapiano, A. (2009). Validation of the Spanish Addiction Severity Index Multimedia Version (S-ASI-MV). Drug Alcohol Dependence, 99, 18-27. doi:10.1016/j.drugalcdep.2008.06.012
• Carise, D., McLellan, A. T., Cacciola, J., Love, M., Cook, T., Bovasso, G. y Lam, V. (2001). Suggested specifications for a standardized Addiction Severity Index database. Journal of Substance Abuse Treatment, 20, 239– 244.
• Caspari, D. (1999). Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 249, 45-49.
• Caton, C. L., Drake, R. E., Hasin, D. S., Dominguez, B., Shrout, P. E., Samet, S. y Schanzer, B. (2005). Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry, 62, 137-145.
• Caton, C. L., Hasin, D. S., Shrout, P. E., Drake, R. E., Dominguez, B., First, M. B., … Schanzer, B. (2007). Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. British Journal of Psychiatry, 190, 105-111.
• Caton, C. L., Samet, S. y Hasin, D. S. (2000). When acute-stage psychosis and substance use co-occur: Differentiating substance-induced and primary psychotic disorders. Journal of Psychiatric Practice, 6, 256-266.
• Celofiga, A., Koprivsek, J. y Klavz, J. (2014). Use of synthetic cannabinoids in patients with psychotic disorders: Case series. Journal of Dual Diagnosis, 10, 168-173. doi: 15504263.2014.929364
• D’Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Yu-te, W., … Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558.
• Dawe, S., Geppert, L., Occhipinti, S. y Kingswell, W. (2011). A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis. Journal of Substance Abuse Treatment, 40, 95-101. doi:10.1016/j.jsat.2010.08.002
• Dekker, N., Meijer, J., Koeter, M., Van den brink, W., Van beveren, N., Kahn, R. S., … Myin-Germeys, I. (2012). Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychological Medicine, 42, 1903-1911. doi:10.1017/S0033291712000062
• Dragogna, F., Mauri, M. C., Marotta, G., Armao, F. T., Brambilla, P. y Altamura, A. C. (2014). Brain metabolism in substance-induced psychosis and schizophrenia: A preliminary PET study. Neuropsychobiology, 70, 195-202. doi:10.1159/000366485
• Drake, R. E., Caton, C. L., Xie, H., Hsu, E., Gorroochurn, P., Samet, S. y Hasin, D. S. (2011). A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. American Journal of Psychiatry, 168, 742-748.
• Dubertret, C., Bidard, I., Adès, J. y Gorwood, P. (2006). Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophrenia Research, 86, 284-290. doi:10.1176/appi.ajp.2011.10071051
• Dumas, P., Saoud, M., Bouafia, S., Gutknecht, C., Ecochard, R., Daléry, J.,... d’Amato, T. (2002). Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Research, 109, 27-35.
• First, M. B, Spitzerm, R. L, Gibbon, M. y Williams, J. B. W. (Eds.) (2002). Structured clinical interview for DSM-IV-TR Axis I disorders (SCID-I). New York, NY: New York State Psychiatric Institute, Biometrics Department.
• Fraser, S., Hides, L., Philips, L., Proctor, D. y Lubman, D. I. (2012). Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophrenia Research, 136, 110-115. doi:10.1016/j.schres.2012.01.022
• García-Álvarez, L., Gomar, J. J., García-Portilla, M. P. y Bobes, J. (2019). Cannabis use and cognitive impairment in schizophrenia and first-episode psychosis. Adicciones, 31, 89-94. doi:10.20882/adicciones.1328
• Hasin, D. S, Trautman, K. D., Miele, G. M., Samet, S., Smith, M. y Endicott, J. (1996). Psychiatric Research Interview for Substance and Mental Disorders (PRISM): Reliability for substance abusers. American Journal of Psychiatry, 153, 1195-1201.
• Kavanagh, D. J., Waghorn, G., Jenner, L., Chant, D. C., Carr, V., Evans, M., … McGrath, J. J. (2004). Demographic and clinical correlates of comorbid substance use disorders in psychosis: Multivariate analyses from an epidemiological sample. Schizophrenia Research, 66, 115-124.
• Kay, S. R., Fiszbein, A. y Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
• Kay, S. R., Opler, L. A. y Lindenmayer, J. P. (1989). The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry, 59-67.
• Kay, S. R. y Sevy, S. (1990). Pyramidical model of schizophrenia. Schizophrenia Bulletin, 16, 537-545.
• Keshavan, M. S. (1999). Development, disease and degeneration in schizophrenia: A unitary pathophysiological model. Journal of Psychiatric Research, 33, 513-521.
• Keshavan, M. S., Gilbert, A. R. y Diwadkar, V. A. (Eds.) (2006). The American Psychiatric Publishing textbook of schizophrenia. Washington, DC: American Psychiatric Publishing.
• Khan, M., Pace, L., Truong, A., Gordon, M. y Moukaddam, N. (2016). Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. American Journal on Addictions, 25, 25-27. doi:10.1111/ajad.12318
• Konings, M., Henquet, C., Maharajh, H. D., Hutchinson, G. y Van os, J. (2008). Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatrica Scandinavica, 118, 209–213.
• Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M. y Miettunen, J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 36, 1115-1130. doi:10.1093/schbul/sbp031
• Large, M., Sharma, S., Compton, M. T., Slade, T. y Nielssen, O. (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Archives of General Psychiatry, 68, 555-561. doi:10.1001/archgenpsychiatry.2011.5
• Lubman, D. I., Cheetham, A. y Yücel, M. (2015). Cannabis and adolescent brain development. Pharmacology & Therapeutics, 148, 1-16. doi:10.1016/j.pharmthera.2014.11.009
• Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M. y Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42, 1262-1269. doi:10.1093/schbul/sbw003
• Mauri, M. C., Di Pace, C., Reggiori, A., Paletta, S. y Colasanti, A. (2017). Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up. Asian Journal of Psychiatry, 29, 117-122. doi:10.1016/j.ajp.2017.04.014
• McGuire, P. K., Jones, P., Harvey, I., Bebbington, P., Toone, B., Lewis, S. y Murray, R. M. (1994). Cannabis and acute psychosis. Schizophrenia Research, 13, 161-167.
• McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., … Argeriou, M. (1992). The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment, 9, 199-213.
• Minichino, A., Senior, M., Brondino, N., Zhang, S. H., Godwlewska, B. R., Burnet, P. W. J., … Lennox, B. R. (2019). Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2019.0970
• Monte, A. A., Calello, D. P., Gerona, R. R., Hamad, E., Campleman, S. L., Brent, J., … Carlson, R. G. (2017). Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: A ToxIC database study. Journal of Medical Toxicology, 13, 146-152. doi:10.1007/s13181-017-0605-9
• Murray, R. M., Englund, A., Abi-Dargham, A., Lewis, D. A., Di Forti, M., Davies, C., … D’Souza, D. C. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89-104. doi:10.1016/j.neuropharm.2017.06.018
• Núñez, L. A. y Gurpegui, M. (2002). Cannabis-induced psychosis: A cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavica, 105, 173-178.
• O’Connell, J., Sunwoo, M., McGorry, P. y O’Donoghue, B. (2019). Characteristics and outcomes of young people with substance induced psychotic disorder. Schizophrenia Research, 206, 257-262. doi:10.1016/j.schres.2018.11.007
• Pencer, A. y Addington, J. (2003). Substance use and cognition in early psychosis. Journal of Psychiatry & Neuroscience, 28, 48-54.
• Peralta, V. y Cuesta, M. J. (1994). Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Research, 53, 31-40.
• Pierre, J. M., Gandal, M. y Son, M. (2016). Cannabis-induced psychosis associated with high potency “wax dabs”. Schizophrenia Research, 172, 211-212. doi:10.1016/j.schres.2016.01.056
• Power, R. A., Verweij, K. J., Zuhair, M., Montgomery, G. W., Henders, A. K., Heath, A. C., … Martin, N. G. (2014). Genetic predisposition to schizophrenia associated with increased use of cannabis. Molecular Psychiatry, 19, 1201-1204. doi:10.1038/mp.2014.51
• Rodriguez-Jimenez, R., Bagney, A., Mezquita, L., Martinez-Gras, I., Sanchez-Morla, E. M., Mesa, N., … Palomo, T. (2013). Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. Schizophrenia Research, 143, 77-83. doi:10.1016/j.schres.2012.10.020
• Rottamburg, D., Ben-Arie, O., Robins, A. H., Teggin, A. y Elk, R. (1982). Cannabis-associated psychosis with hypomanic features. Lancet, 18, 1364-1366.
• Rubio, G., Marín-Lozano, J., Ferre, F., Martínez-Gras, I., Rodriguez-Jimenez, R., Sanz, J., … Palomo, T. (2012). Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis. Comprehensive Psychiatry, 53, 1063-1070. doi:10.1016/j.comppsych.2012.04.013
• Sánchez-Blázquez, P., Rodríguez-Muñoz, M. y Garzón, J. (2014). The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: Implications in psychosis and schizophrenia. Frontiers in Pharmacology, 4, 169. doi:10.3389/fphar.2013.00169
• Sara, G. E., Burgess, P. M., Malhi, G. S., Whiteford, H. A. y Hall, W. C. (2014). The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. Journal of Clinical Psychiatry, 75, 349-356. doi:10.4088/JCP.13m08878
• Shah, D., Chand, P., Bandawar, M., Benegal, V. y Murthy, P. (2017). Cannabis induced psychosis and subsequent psychiatric disorders. Asian Journal of Psychiatry, 30, 180-184. doi:10.1016/j.ajp.2017.10.003
• Soto-Brandt, G., Portilla Huidobro, R., Huepe Artigas, D., Rivera-Rei, Á., Escobar, M. J., Salas Guzmán, N.,... Castillo-Carniglia, Á. (2014). Evidencia de validez en Chile del Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Adicciones, 26, 291-302.
• Starzer, M. S. K., Nordentoft, M. y Hjorthøj, C. (2018). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry, 175, 343-350. doi:10.1176/appi.ajp.2017.17020223
• Statistical Package for the Social Sciences. (2011). SPSS Base 20.0 User’s Guide. Chicago, IL: SPSS Inc.
• Stone, J. M., Fisher, H. L., Major, B., Chisholm, B., Woolley, J., Lawrence, J., … Young, A. H. (2014). Cannabis use and first-episode psychosis: Relationship with manic and psychotic symptoms, and with age at presentation. Psychological Medicine, 44, 499-506. doi:10.1017/S0033291713000883
• Suárez-Pinilla, P., López-Gil, J. y Crespo-Facorro, B. (2014). Immune system: a posible nexus between cannabinoids and psychosis. Brain, Behavior, and Immunity, 40, 269-282. doi:10.1016/j.bbi.2014.01.018
• Thompson, A., Marwaha, S., Winsper, C., Everard, L., Jones, P. B., Fowler, D., … Birchwood, M. (2016). Short-term outcome of substance-induced psychotic disorder in a large UK first episode psychosis cohort. Acta Psychiatrica Scandinavica, 134, 321-328. doi:10.1111/acps.12623
• Torrens, M., Serrano, D., Astals, M., Perez-Dominguez, G. y Martin-Santos, R. (2004). Diagnosing comorbid psychiatric disorders in substance abusers: Validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. American Journal of Psychiatry, 161, 1231-1237.
• Van Dijk, D., Koeter, M. W., Hijman, R., Kahn, R. S. y Van den Brink, W. (2012). Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. Schizophrenia Research, 137, 50-57. doi:10.1016/j.schres.2012.01.016
• Volkow, N. D. (2009). Substance use disorders in schizophrenia--clinical implications of comorbidity. Schizophrenia Bulletin, 35, 469-472. doi:10.1093/schbul/sbp0.16
• Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. y Dickinson, D. (2012). Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Research, 137, 246-50. doi:10.1016/j.schres.2012.01.031
• Weibell, M. A., Joa, I., Bramness, J., Johannessen, J. O., McGorry, P. D., Ten Velden Hegelstad, W. y Larsen, T. K. (2013). Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry, 13, 319. doi:10.1186/1471-244X-13-319
• Wilson, L., Szigeti, A., Kearney, A y Clarke, M. (2018). Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review. Schizophrenia Research, 197, 78-86. doi:10.1016/j.schres.2017.11.001
• Zammit, S., Moore, T. H., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M. y Lewis, G. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. British Journal of Psychiatry, 193, 357-363. doi:10.1192/bjp.bp.107.046375